Core Viewpoint - InMode Ltd. anticipates releasing its financial results for Q4 and full year 2024 on February 6, 2025, with preliminary results indicating stronger-than-expected challenges in the aesthetics industry due to macroeconomic factors [2][7]. Financial Performance - Expected revenue for Q4 2024 is projected to be between $97.0 million and $97.5 million, while the full year 2024 revenue is estimated to be in the range of $394.0 million to $394.5 million [7]. - The non-GAAP gross margin for the full year 2024 is anticipated to be between 80% and 81% [7]. - Revenue for the full year 2025 is projected to be between $395 million and $405 million [7]. Company Overview - InMode is a global provider of innovative medical technologies, focusing on devices that utilize novel radiofrequency technology for various medical applications [8]. - The company aims to enhance surgical procedures and improve existing treatments through its minimally invasive RF technologies, offering a comprehensive product line across multiple medical fields [8].

Company Performance - InMode Ltd reports impressive net income growth driven by the sale of non-invasive surgical products [1] - The company recently launched two new platforms, Define and Envision, which are expected to contribute to future business growth [1] Analyst Background - The analyst has nearly 14 years of experience in the financial industry, having worked for an equity research firm in NY, an investment fund in Mexico, and an investment bank in Ireland [1] - The analyst currently focuses on mature industries such as mining, oil and gas, and real estate, and targets investments with an internal rate of return of 5%-7% [1] - The analyst does not invest in business models they do not understand and appreciates M&A deals, deep value investments, and dividend investing [1] Disclosure - The analyst holds a beneficial long position in InMode Ltd through stock ownership, options, or other derivatives [2] - The article expresses the analyst's own opinions and they are not receiving compensation for it other than from Seeking Alpha [2] - The analyst has no business relationship with any company mentioned in the article [2]

Core Insights - InMode Ltd. reported consolidated financial results for Q3 2024, showing a revenue increase of 5.8% year-over-year, reaching $130.2 million, despite challenges in demand and operational adjustments [2][5][4]. Financial Performance - Q3 2024 GAAP revenue was $130.2 million, including $31.9 million from pre-orders, compared to $123.1 million in Q3 2023 [2][5]. - Revenue from consumables and services decreased by 11% year-over-year to $15.8 million [2]. - GAAP operating income for Q3 2024 was $48.2 million, with a non-GAAP operating income of $52.2 million [2][8]. - The total cash position as of September 30, 2024, was $684.9 million, comprising cash, cash equivalents, marketable securities, and short-term bank deposits [2]. Profitability Metrics - GAAP net income for Q3 2024 was $51.0 million, or $0.65 per diluted share, compared to $46.5 million, or $0.54 per diluted share, in Q3 2023 [8][2]. - Non-GAAP net income for Q3 2024 was $55.0 million, or $0.70 per diluted share, compared to $53.1 million, or $0.61 per diluted share, in Q3 2023 [8][2]. Gross and Operating Margins - GAAP gross margin for Q3 2024 was 82%, down from 84% in Q3 2023 [6][7]. - GAAP operating margin for Q3 2024 was 37%, compared to 38% in Q3 2023, while non-GAAP operating margin was 40%, down from 43% [7]. 2024 Financial Outlook - The full-year 2024 revenue guidance has been revised to between $410 million and $420 million, down from the previous guidance of $430 million to $440 million [9]. - Non-GAAP gross margin is expected to be between 81% and 82%, and non-GAAP income from operations is projected to be between $140 million and $145 million [9].

Core Points - InMode Ltd. has been granted a preliminary injunction by the U.S. District Court for the Central District of California against sellers involved in the unlawful counterfeit sales of Morpheus8 radiofrequency devices and accessories [1] - The court's order includes a Temporary Restraining Order (TRO) due to strong evidence supporting the protection of InMode's trademarks and the public interest [1] - The injunction has resulted in the freezing of assets and account listings of the involved counterfeit sellers [1] Company Actions - InMode emphasizes its zero tolerance for dishonest business practices and prioritizes public safety [2] - The company plans to continue enforcement actions against sellers of counterfeit products to mitigate harm caused by these devices [2] - Patients can verify the authenticity of Morpheus8 devices by locating authorized providers through InMode's website [2] Company Overview - InMode is a leading global provider of innovative medical technologies, focusing on devices that utilize novel radiofrequency technology [3] - The company develops and markets a comprehensive line of products for various medical fields, including plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology [3] - More information about InMode's technologies can be found on their official website [3]

Wall Street expects a year-over-year decline in earnings on higher revenues when InMode (INMD) reports results for the quarter ended September 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on October 30, 2024, might help the stock move higher if these key numbers are better than expec ...

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks. Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors use fundamental analysis and ...

Expects Q3 Revenue Between $130.0 Million -$130.1 Million (including $31.9 Million in Revenue from First Half of 2024 Pre-orders), Decreases Full Year 2024 Guidance to $410 Million-$420 Million Conference call to be held on Wednesday, October 30, 2024, at 8:30 a.m. Eastern Time YOKNEAM, Israel, Oct. 10, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the third quarter of 2024 b ...

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers. Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use fundamental analysis and traditional va ...

I specialize in biotech and healthcare investment analysis, integrating clinical expertise with a solid foundation in business strategy. My approach leverages detailed risk-return charts and DCF analyses to clearly communicate the investment potential and associated risks. I advocate for a barbell portfolio strategy, with 90% allocated to secure assets such as Treasuries and broad-market ETFs, and 10% to high-alpha stocks. This balanced approach ensures that all recommendations are made within a context of ...

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks. Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors use tried-and-true metrics an ...